Kornimate/medical-research-clean huggingface dataset:
ultrasound assessed gastric volume in the fasted pediatric cerebral palsy patients

Conditions: Cerebral Palsy

Summary: in patients with cerebral palsy, delayed gastric emptying and esophageal sphincter dysfunction are very commonly observed. pulmonary aspiration of gastric contents causes aspiration pneumonia, which greatly affects patients' prognosis, including hospital stay and mortality. in the case of patients with cerebral palsy, there is a limitation in respiratory function, so more attention is required. therefore, this study aims to evaluate the risk of aspiration by measuring gastric volume after fasting for surgery in children with cerebral palsy.


Eligibility criteria:
inclusion criteria: * patients with cerebral palsy under the age of 18 scheduled surgery under general anesthesia exclusion criteria: * the patient who feed through levin tube or gastrostomy tube * refusal to participate
a study to evaluate the efficacy and safety of pf-06882961 in adults with obesity

Conditions: Obesity

Summary: the purpose of this clinical trial is to learn about the safety and effects of the study medicine (called pf-06882961) for the potential treatment of obesity. the study will compare the experiences of participants taking the study medicine (pf-06882961) to those of participants who take placebo (a look- alike substance that contains no active study medicine). the aim is to measure the body's response to the study medicine, including any changes in participants' body weight, waist and hip measurements, how well they tolerate the study medicine, and to measure levels of the study medicine in participants' blood. this study is seeking participants who have obesity, who do not have diabetes and who have had a stable body weight and not participated in a formal weight loss program in the 90 days before the study. the study medicine or placebo will be taken as tablets by mouth 2 times a day (1 time in the morning and 1 time in the evening). there are 3 groups of participants (called cohorts) in this study. for participants in cohorts 1 and 2, total study participation will be about 9 months, with 15 planned study visits (14 visits to the study clinic and 1 telephone call). for participants in cohort 3, total study participation will be about 10 months, with 21 planned study visits (12 visits to the study clinic and 9 telephone calls).


Eligibility criteria:
inclusion criteria: * participants with obesity, defined as a body mass index greater than or equal to 30.0 kg/m2 * stable body weight, defined as \<5 kg change (per participant report) for 90 days before visit 1 exclusion criteria: * any condition possibly affecting drug absorption * current or prior diagnosis of type 1 or type 2 diabetes mellitus or secondary forms of diabetes * history of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or transient ischemic attack within 6 months prior to visit 1 * any malignancy not considered cured * personal or family history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia syndrome type 2 or suspected mtc * history of acute pancreatitis within 180 days (6 months) prior to visit 1 or any history of chronic pancreatitis * symptomatic gallbladder disease * medical history or characteristics suggestive of genetic or syndromic obesity or obesity induced by other endocrinological disorders * history of major depressive disorder or other severe psychiatric disorders within the last 2 years * any lifetime history of a suicide attempt * known medical history of active liver disease, including chronic active hepatitis b or c, or primary biliary cirrhosis * known history of hiv * supine blood pressure greater than or equal to 160 mmhg (systolic) or greater than or equal to 100 mmhg (diastolic) * clinically relevant ecg abnormalities * positive urine drug screen * participation in a formal weight reduction program within 90 days prior to visit 1

Keywords: weight loss
a long term safety study of suvorexant in participants with primary insomnia (mk-4305-009 am3)

Conditions: Insomnia

Summary: this study will establish the safety and tolerability of suvorexant (mk-4305) when administered for up to 14 months. participants will be randomized to receive suvorexant or placebo for a 12-month double-blind (db) treatment phase. participants who complete the 12-month db treatment phase will enter a 2-month db randomized discontinuation phase. at the time of initial randomization, participants assigned to receive suvorexant during the initial 12-month treatment phase will be simultaneously randomized, in a 1:1 ratio, to receive either suvorexant or placebo during the 2-month randomized discontinuation phase. participants randomized to receive placebo in the initial 12-month treatment phase will continue to receive placebo during the 2-month randomized discontinuation phase. the first 3 nights of the randomized discontinuation phase are referred to as the run-out phase, and will assess rebound and withdrawal.


Eligibility criteria:
inclusion criteria: * diagnosis of primary insomnia * participant is able to read, understand, and complete questionnaires and diaries * if female, participant and partner both agree to use acceptable contraception. if male partner does not use an effective form of contraception, female participant must use 2 acceptable forms of contraception * if ≥65 years of age, score of ≥25 on the mini mental state examination (mmse) exclusion criteria: * if female, participant is pregnant * participant expects to donate eggs or sperm during the study * recent and/or active history of a confounding neurological disorder * history of clinically unstable cardiovascular disorder within the last 6 months * lifetime history of bipolar disorder * psychiatric condition that requires treatment with a medication prohibited by the study, or any other psychiatric condition that would interfere with the participant's ability to participate in the study * history of substance abuse/dependence * history of cancer ≤5 years prior to study participation except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer * evidence of suicidality (based on a score of 2 on the quick inventory of depressive symptomatology self-report 16-item (\[qids-sr16\] suicide item #12) * participant has travelled across \>3 time zones or \>3 hour time difference in the last 2 weeks * history of permanent night shift work or rotating day/night shift work in the past 2 weeks * body mass index (bmi) \>40 kg/m\^2
a phase ii open label study of xilonix in subjects with pyoderma gangrenosum

Conditions: Pyoderma Gangrenosum

Summary: the purpose of this study is to determine if treatment with xionix will improve wound healing for patients with pyoderma gangrenosum.

xbiotech owned bermekimab and sponsored and completed study prior to dec 30, 2019.

Eligibility criteria:
inclusion criteria: 1. age: ≥18 2. history of pyoderma gangrenosum with or without other systemic disease. exclusion criteria: 1. treatment with any biologicals (including intravenous immunoglobulin) or investigational agents within the last 4 weeks (or 5 half-lives, whichever is longer). 2. treatment with corticosteroids or cyclosporine within the last 2 weeks.

Keywords: pyoderma gangrenosum
a study of the current medical practice and outcomes in the treatment of type 2 diabetes mellitus in an office setting (mk-0431-199)

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to collect information of the risk profile of patients with type 2 diabetes mellitus, their treatment concerning meeting the guidelines for treatment of diabetic patients type 2 published by the deutsche diabetes gesellschaft (ddg) on october 13, 2008


Eligibility criteria:
inclusion criteria: - newly diagnosed with type 2 diabetes in whom treatment with metformin in the individual maximal tolerated dose (at least four weeks on stable dose) resulted in hba1c \>6.5% - no contraindication or intolerability to metformin exclusion criteria: - currently being administered a combination therapy for the treatment of their type 2 diabetes
telerehabilitation for tmd

Conditions: Temporomandibular Disorder; TMJ Disc Displacement With Reduction; TMJ Disc Displacement Without Reduction; Masticatory Myofascial Pain; TMJ Arthralgia; TMD Headache

Summary: this study will compare after physical therapy for temporomandibular disorders (tmd) performed either in-person or virtually using telerehabilitation. comparing diagnostic reliability and quality-of-life outcomes in each group will determine (based on a 10% margin) whether delivering physical therapy via telerehabilitation is as good as standard in-person care for these individuals. long term outcomes including patient satisfaction, cost-effectiveness analysis, and functional status will describe the feasibility of telerehabilitation as a management intervention for this population.


Eligibility criteria:
inclusion criteria: * 18-70 years old * referred to pt with ≥1 tmd subtype diagnosis * pi has no previous knowledge of the participant's diagnosis * email access * possession of any device that can be positioned for hands-free tr visits (tr group only) * willingness and ability to comply with all study requirements and pt program * able to provide informed consent exclusion criteria: * non-english speakers * permanent residence outside of the state of minnesota (tr group only) * women in the last trimester of pregnancy * referred for post-surgical rehabilitation * severe chronic pain as identified by level 4 classification on the gcps * current diagnosis or existence of the following conditions that can limit response to pt and participation in study activities: 1. neuropathic pain 2. fibromyalgia and/or generalized widespread pain on both sides of the body in ≥3 areas above and below the waist 3. rheumatoid arthritis or juvenile idiopathic arthritis 4. dystonia or other movement disorder 5. fractures and/or recent jaw or facial trauma 6. malignancies 7. current substance abuse

Keywords: temporomandibular disorders tmd telerehabilitation telehealth physical therapy pt
cognitive rehabilitation in patients with depression

Conditions: Depression

Summary: depression is a highly prevalent and debilitating mental disorder, ranked one of the leading causes of disability worldwide. several studies have identified neuropsychological deficits in populations of depressed patients affecting domains including attention, memory and executive functioning. these deficits often persist even in patients whose depressive symptoms have remitted. cognitive impairment in depression represent a core feature of depression, and a valuable target for intervention. identification of methods that would lead to amelioration would be of great clinical interest, and cognitive rehabilitation (cr) could be a potential way of achieving this. to date few studies on cognitive rehabilitation in depression has been conducted, but the preliminary results are promising. still the demonstration of long-term effects and evidence relating to improved daily life executive functioning (i.e., generalization) is lacking. in the present study different group-based cognitive rehabilitation interventions will be compared. the aim of the study is to investigate if a group-based "brain training" intervention can improve executive function in patients with active and remitted depression. efficacy will be assessed immediately after intervention, but also six months after the intervention.


Eligibility criteria:
inclusion criteria: * completed treatment for mild or moderate mdd * evidence of executive dysfunction in everyday life determined by (a) a structured interview or (b) a self-report behavior rating inventory of executive function (brief) t-score \< 55. exclusion criteria: * cognitive, sensory, physical, or language impairment affecting the capacity to complete the training program. * premorbid neurological disease or insult and/or comorbid neurological disorder. * reported ongoing alcohol or substance abuse. * psychotic disorders. * actively suicidal. * personality disorder sever enough to interfere with the protocol. * not fluent in norwegian language.

Keywords: rehabilitation
improving maternal mental health & sud screening and treatment

Conditions: Mental Health Issue; Substance Use Disorders; Postpartum Depression; Postpartum Anxiety

Summary: the purpose of the study is to compare a text message-based mental health and substance use screening and referral to a treatment program, called listening to women and pregnant and postpartum people (ltwp), to standard of care in-person mental health and substance use screening to look at rates of treatment attendance and retention in treatment. participation would involve completing online questionnaires. you may be eligible to participate if you are age 18-45 years, are pregnant and entering prenatal care in one of musc's ob clinics, and attended a prenatal appointment at an musc clinic.

aim 1: to determine differences in rates of treatment attendance and retention for perinatal mood and anxiety disorders (pmads) and perinatal substance use disorders (psuds) between participants assigned to ltwp, compared to sbirt. aim 2: to determine differences in patient-reported outcomes (pros) including depressive symptoms, quality of life, substance use, and maternal functioning and well-being measured at baseline and 2, 5, 8, and 11 months postpartum.

Eligibility criteria:
aim 1: this study is a cluster rct step wedge design so we are randomizing on the clinic level, not the individual level. the clinics are made up of 4 "wedges" (3 clinics/wedge). pregnant women receiving prenatal care in these clinics will receive sbirt as part of usual care. clusters of clinics will be randomized to an ltwp start date where they will transition from sbirt to ltwp for the purposes of screening and referral to treatment. ehr data collection (ppp): inclusion: 1. age 18-45 2. pregnant and entering prenatal care in one of musc's ob clinics 3. attended a prenatal appointment at an musc clinic exclusion: a.) primary language is not english or spanish aim 2: study assessments at baseline and 2, 5, 8, and 11 months postpartum (ppp): inclusion: 1. age 18-45 years 2. pregnant 3. attended an initial prenatal appointment at an musc ob clinic exclusion: 1. unable to complete study assessments 2. primary language is not english or spanish
mini-open subpectoral biceps tenodesis

Conditions: Bicep Tendinitis

Summary: surgical management of long head of biceps (lhb) lesions is frequent, often alongside other shoulder issues. when conservative treatment fails, tenotomy (for low-demand patients) or tenodesis (preferred for active individuals) is performed. subpectoral tenodesis offers advantages, and this study assesses a novel press-fit bony plug technique for this approach, evaluating its safety and efficacy.


Eligibility criteria:
inclusion criteria: * patients with biceps tendon pathologies after failure of conservative measures: biceps tenosynovitis, recurrent subluxation, or slap lesions. * young and middle-aged individuals (20-60 years old). exclusion criteria: * patients with avascular necrosis or arthritis. * extensive bone loss. * poor bone density. * active infection.
efficacy and safety of hemoperfusion or plasma exchange compared to standard medical therapy in patients with acute on chronic liver failure

Conditions: Acute-On-Chronic Liver Failure

Summary: the study is done with the aim of finding the association between the bilirubin and bile acids / damps molecule with organ failures and sepsis in the patients with acute on chronic liver failure . in this study there are 2 parts in the first part people who satisfy the eligibility criteria will be recruited and blood samples will be taken and above mentioned molecules will be analyzed and association ,if any with occurrences of organ failures / new onset sepsis will be analyzed . in the second part of the study the patients who meet the criteria will be randomized to either receive standard medical therapy or with either haemoperfusion or therapeutic plasma exchange with standard medical therapy . blood samples will be taken and stored, bile acids (primary and secondary bile acids, bilirubin and damps molecules will be analysed .the patients are followed for 90 days , then statistical analysis will be done to find the association with organ failures and new onset sepsis .


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with aclf as per apasl criteria will be included. 2. age : 18-65 yrs. exclusion criteria: 1. patient with ischemic heart disease 2. patient with chronic obstructive disease. 3. patient with hepato cellular carcinoma. 4. patient with extra hepatic malignancy. 5. patient with chronic renal insufficiency.
patient-individualized peptide vaccination based on tumor-specific mutations in children and young adults with primary/relapsed all

Conditions: Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults

Summary: the aim of this clinical study is to evaluate the feasibility and safety of an individualized peptide vaccination approach in patients with acute lymphoblastic leukemia (all). for this purpose, tumor-specific mutations are analyzed by comparative exome sequencing of tumor and healthy reference tissue. expression of variants is further validated by rna sequencing. in a second step, hla-binding (human leukocyte antigen-binding) peptides derived from mutated protein sequences are selected for vaccination. the peptides are administered as a vaccination cocktail with adjuvant gm-csf and imiquimod over a course of 9 months and a total of 16 vaccinations. primary objective is the de novo induction of a specific t cell response without unacceptable toxicity and acute gvhd (graft versus host disease).


Eligibility criteria:
inclusion criteria: * pediatric patients and young adults with all (t, b, pro-b, pre-b or c-all) ≥cr3 or with ≥1st relapse after stem cell transplantation (sct); or patients in ≤cr2 who have received sct without having reached a sufficient molecular remission prior to, or after sct (defined as mrd ≥10\^-4); or patients with initially refractory disease to standard treatment who could proceed to stem cell transplantation with alternative treatment options. * hematological remission has to be reached (\<5% blasts in bone marrow or detectable minimal residual disease (mrd) ≤5x10\^-2) after salvage chemotherapy and/or subsequent sct. exclusion criteria: * frank relapse (\>5% leukemic blasts). * ejection fraction \ 4mg/dl, transaminases \>400 units/ml; severe infection (hiv, hepatitis), acute gvhd iii-iv or chronic gvhd. * significant psychiatric disabilities, uncontrolled seizure disorders or severe peripheral neuropathy/ leukoencephalopathy. * signs of autoimmune disease (i.e. idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia). * need for immunosuppressive drugs. * no tumor material available for exome sequencing.

Keywords: individualized peptide vaccination immunotherapy tumor-specific mutations neoantigens
diffusion tensor (dti) for the assessement of therapeutic evolution of patients with acute lumbar radiculalgia

Conditions: Lumbar Radiculopathy; Magnetic Resonance Imaging; Diffusion Tensor Imaging

Summary: diffusion tensor imaging (dti) is a non-invasive mri technique offering a functional approach that provides morphological information about the microstructures of the nerve roots. dti is a widely used neuroimaging technique and is a current topic of research in the field of peripheral nerve imaging.the aim of the study is to determine the prognostic quality of the dti parameters to predict the therapeutic evolution of patients with lumbar radiculalgia at 6 months.


Eligibility criteria:
inclusion criteria: * age ≥ 18 ans * patient with lumbar radiculalgia (l4, l5 or s1) * pain vas (visual analog scale) \> 30/100 * less than 3 months of evolution * with a radiculalgia superior or equal to lumbalgia * disco radicular conflict, verified by mri * able to receive information * affiliated to french social security exclusion criteria: * history of chronic lumbalgia and radiculalgia * history of lumbar surgery * recent episode (less than 6 months) with the same radicular topography * bilateral radicular compression on mri * patient requiring emergency surgery * evolutive disease interfering with pain assesment (neoplasia, inflammatory rheumatism, peripheral neuropathy, central neurological disease) * mri contraindication

Keywords: lumbar radiculopathy magnetic resonance imaging diffusion tensor imaging prognostic
mellowing mind: comparing two technology based mindfulness interventions for stress impacted by covid-19 in underserved communities

Conditions: Worry; Stress

Summary: the purpose of this study is to examine the comparative effectiveness of two technology-based mindfulness based stress reduction (mbsr) programs (one via video/teleconference and one via a smartphone app) for reducing worry, anxiety and/or related mental health effects of stress in members of identified underserved communities, which were highly impacted by the covid-19 pandemic.

the purpose of this randomized controlled study is to examine the comparative effectiveness of two technology-based mindfulness based stress reduction (mbsr) programs (one via video/teleconference and one via a smartphone app) for reducing worry, anxiety, and/or related mental health effects of stress in members of identified underserved communities, which were highly impacted by the covid-19 pandemic. participants will be randomly assigned to a teleconference mbsr program, a mbsr smartphone app program, or a waitlist control group. each intervention includes participation in a 9-week (8 sessions plus an introduction) mindfulness intervention that consists of instruction and daily practice. questionnaires and semi-structured interviews will be administered at mid-intervention, post-intervention, and one-month and three-month follow-up points. it is hypothesized that participants in the two intervention groups will show measurable and sustained improvement in the primary outcome, worry, as well as in the secondary outcomes, anxiety and related mental health effects. it is further hypothesized that the smartphone app mindfulness intervention will show similar effectiveness to the teleconference mindfulness intervention.

Eligibility criteria:
inclusion criteria: * 18 years and older * significant worry as per the penn state worry questionnaire-abbreviated \[pswq-a\] * fluent in english * reside in one of the local city zip codes, identified as underserved, and primarily african american, communities exclusion criteria: * severe depression as per patient health questionnaire \[phq-9\] * active suicidal intent as per phq-9 question 9 * diagnosis of psychosis, or bipolar disorder, or moderate or severe substance use disorder in the past month as per self report * cognitive impairment as per (modified) short portable mental status questionnaire \[spmsq\] * currently receiving psychotherapy or behavioral counseling, including mbsr * change in psychotropic medications within the last month as per self report * unable to communicate in a way that would allow for participation in screenings or sessions

Keywords: mindfulness based stress reduction community based research